ImmuneOnco Biopharmaceuticals (Shanghai), Inc. operates as an early-stage biopharmaceutical company which develops and commercializes novel cancer immunotherapeutic products. The company is headquartered in Shanghai, Shanghai and currently employs 195 full-time employees. The company went IPO on 2023-09-05. The firm's main businesses include the development of biotechnology for the systemic utilization of innate and adaptive immunity, and the development of next-generation tumor immunotherapies, which primarily focus on the adaptive immune system. The firm's core product IMM01 is an innovative CD47-targeted molecule. The firm mainly operates its businesses in the domestic and overseas markets.
01541.HK stock price ended at $4.58 on 星期五, after rising 3.39%
On the latest trading day Feb 13, 2026, the stock price of 01541.HK rose by 3.39%, climbing from $4.58 to $4.58. During the session, the stock saw a volatility of 5.53%, with prices oscillating between a daily low of $4.34 and a high of $4.58. Notably, trading volume dropped by 153.0K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 855.0K shares were traded, equating to a market value of approximately $1.9B.